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Abstract 25 
Although high dose omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation 26 
reduces exercise- and hyperpnoea-induce bronchoconstriction (EIB/HIB), there are concurrent 27 
issues with cost, compliance, and gastrointestinal discomfort. It is thus pertinent to establish the 28 
efficacy of lower n-3 PUFA doses. Eight male adults with asthma and HIB and 8 controls without 29 
asthma were randomly supplemented with two n-3 PUFA doses (6.2 g/d (3.7g EPA and 2.5g DHA) 30 
and 3.1 g/d (1.8g EPA and 1.3g DHA)) and a placebo, each for 21 days followed by 14 days 31 
washout. A eucapnic voluntary hyperpnoea (EVH) challenge was performed before and after 32 
treatments. Outcome measures remained unchanged in the control group. In the HIB group, the 33 
peak fall in forced expiratory volume in 1 s (FEV1) after EVH at day 0 (-1005 (SD 520) mL, -30 34 
(SD 18) %) was unchanged after placebo. The peak fall in FEV1 was similarly reduced from day 0 35 
to day 21 of 6.2 g/d n-3 PUFA (-1000 (SD 460) mL, -29 (SD 17) % vs. -690 (SD 460) mL, -20 (SD 36 
15) %) and 3.1 g/d n-3 PUFA (-970 (SD 480) mL, -28 (SD 18) % vs. -700 (SD 420) mL, -21 (SD 37 
15) %) (P<0.001). Baseline fraction of exhaled nitric oxide was reduced by 24% (P=0.020) and 38 
31% (P = 0.018) after 6.2 and 3.1 g/d n-3 PUFA, respectively. Peak increases in 9α, 11ß PGF2 after 39 
EVH were reduced by 65% (P=0.009) and 56% (P=0.041) after 6.2 and 3.1 g/d n-3 PUFA, 40 
respectively. In conclusion, 3.1 g/d n-3 PUFA supplementation attenuated HIB and markers of 41 
airway inflammation to a similar extent as a higher dose. Lower doses of n-3 PUFA thus represent a 42 
potentially beneficial adjunct treatment for adults with asthma and EIB. 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
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Introduction 54 
Exercise-induced bronchoconstriction (EIB) is a prominent asthma phenotype affecting an 55 
estimated 90% of asthma patients and up to 50% of elite athlete populations(1). EIB is characterised 56 
by transient airway narrowing during and/or after exercise(2) and is ascribed to airway drying 57 
leading to degranulation of inflammatory cells and release of inflammatory mediators(3, 4). Inhaled 58 
corticosteroids and short- and long-acting β2-agonists are effective therapies, but they are not 59 
curative and do not modify disease progression(5). Furthermore, inhaled corticosteroids adherence is 60 
notoriously poor and may have undesirable side effects, while chronic β2-agonist use results in 61 
tolerance(5, 6). Development of therapies that modulate asthma immunopathology without adverse 62 
side effects is therefore desirable.  63 
One potential candidate therapy involves the omega-3 long chain polyunsaturated fatty acids 64 
(n-3 PUFA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)(7). Dietary 65 
supplementation of n-3 PUFA increases cell membrane EPA and DHA content and reduces n-6 66 
arachidonic acid content(8). This subsequently reduces the synthesis of the pro-inflammatory 67 
arachidonic acid-derived eicosanoids cysteinyl leukotrienes and prostaglandins. EPA and DHA may 68 
also increase synthesis of resolvin and protectin compounds through the cyclooxygenase and 69 
lipoxygenase pathways which are involved in the resolution of inflammation. These mechanisms 70 
are thought to be central to the well-established anti-inflammatory effects of n-3 PUFA(8), which 71 
provide a rationale for the use of n-3 PUFA in asthma(7). To date, however, the role of EPA and 72 
DHA in the management of asthma and EIB remains uncertain(9-14). Early research showed that 73 
supplementation of 5.4 g/d n-3 PUFA (3.2 g/d EPA and 2.2 g/d DHA) for 10 weeks in adults with 74 
asthma reduced leukotriene generation and neutrophil chemotactic responsiveness, but did not 75 
reduce bronchoconstriction after cycling exercise and a histamine challenge(9). Similarly, 76 
supplementation of 6.0 g/d n-3 PUFA (4.0 g/d EPA and 2.0 g/d DHA) for 3 weeks in adults with 77 
asthma did not attenuate bronchoconstriction or markers of airway inflammation in response to a 78 
mannitol challenge test(12). Conversely, supplementation of 5.4 g/d n-3 PUFA (3.2 g/d EPA and 2.2 79 
g/d DHA) for 3 weeks in elite athletes(10) and physically active asthmatic males(11, 15) abolished EIB. 80 
Subsequent studies showed that supplementation of n-3 PUFA (3.2 g/d EPA and 2.0 g/d DHA) 81 
reduced bronchoconstriction and markers of airway inflammation after eucapnic voluntary 82 
hyperpnoea (EVH)(16) and that n-3 PUFA (~3.2 g/d EPA and ~2.0 g/d DHA) was as effective as a 83 
leukotriene modifier(17).  84 
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Given the lack of reported risk in taking n-3 PUFA, the American Thoracic 85 
Society/European Respiratory Society (ATS/ERS) guidelines suggest that the latter studies offer 86 
some support for the consumption of n-3 PUFA by interested individuals with EIB(10, 11, 17). In 87 
contrast however, recent practice parameter (14) cautions the recommendation for n-3 PUFA use in 88 
EIB based on more recent findings(12, 18). When considering the practicalities associated with n-3 89 
PUFA supplementation for asthma management, previous studies have used doses of 5.2-6.0 g/d. 90 
Such doses require individuals to ingest between 8-20 capsules of commercial fish oil daily, which 91 
has implications for cost, compliance, and gastrointestinal discomfort(19, 20). In a single-blind study 92 
an alternative flavoured beverage delivery was investigated (3.0 g/d EPA, 3.0 g/d DHA and 30 µg 93 
of vitamin D3) but failed to show any attenuation in HIB or markers of airway inflammation 94 
(FENO, urinary 9α, 11ß PGF2 and cysteinyl leukotriene E4)
(18). However, no measure of compliance 95 
to the treatment was made and participants included had mild asthma or did not have a physician 96 
diagnosis of asthma. It is therefore pertinent to establish if lower doses of n-3 PUFA are effective in 97 
reducing EIB. With respect to the simulation of EIB under laboratory conditions, an EVH challenge 98 
causes a highly reproducible hyperpnoea-induced bronchoconstriction (HIB) (a surrogate for EIB) 99 
in adults with asthma(21) which makes this an attractive challenge test to evaluate the effects of n-3 100 
PUFA treatments on airway hyper responsiveness.  Thus, the aim of the current study was to 101 
compare the effects of a 6.2 g/d n-3 PUFA dose with a half dose of 3.1 g/d n-3 PUFA on HIB and 102 
markers of airway inflammation in adults with asthma. Provisional data from the study was 103 
previously part published in abstract form(22). 104 
 105 
Methods 106 
Participants 107 
Sixteen non-smoking, recreationally active men (completing ≥6-h of endurance exercise per 108 
week) provided written, informed consent to participate in the study (Table 1). Eight participants 109 
formed a HIB group and 8 formed a control group. Inclusion criteria for the HIB group were: 110 
physician diagnosis of asthma, a baseline FEV1 >65% of predicted
(23), and a ≥10% fall in FEV1 111 
following initial EVH screening(24, 25). The HIB group were on step 1-3 of the stepwise approach to 112 
asthma control, indicating well-controlled asthma using either reliever medication (short acting β2-113 
agonsit) alone or in combination with controller medication (low dose inhaled corticosteroid and/or 114 
long-acting β2-agonist(26) (Table 1). Inclusion criteria for the control group were: a baseline FEV1 115 
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>65% of predicted and a <10% fall in FEV1 following initial EVH screening. Participants avoided 116 
exercise for 24-h before an EVH test, and the HIB group ceased their medication as previously 117 
descried(21, 24). On EVH test days, participants abstained from caffeine and alcohol and arrived at the 118 
laboratory >2-h post-prandial(27, 28). Participants were instructed to abstain from consumption of n-3 119 
PUFA supplements and eat no more than 2 oily fish meals per week for 3 weeks prior to the study 120 
and throughout the study(11). Participants were free from acute upper respiratory tract infections 121 
throughout the study.  122 
Experimental Design and Protocol 123 
This study was conducted in accordance with the Declaration of Helsinki and all procedures 124 
were approved by the Nottingham Trent University Human Ethics Committee (Approval No. 186; 125 
Clinical trial No. ISRCTN80857707). The study adopted a counter balanced, double-blind, placebo-126 
controlled crossover design over 14 consecutive weeks (Figure 1).  127 
Participants were randomised (block randomisation) to receive three 21 day treatments each 128 
separated by a 14 day washout period. All treatments involved daily oral consumption of 8 capsules 129 
(CRODA International Plc, Snaith, UK). Four capsules were taken in the morning and four in the 130 
afternoon with a recommendation to take with food. The three treatments were: 6.2 g/d n-3 PUFA 131 
(3.7 g EPA and 2.5 g DHA), 3.1 g/d n-3 PUFA (1.8 g EPA and 1.3 g DHA) (INCROMEGATM 132 
TG4030, CRODA, UK) and placebo (CRODAMOLTM GTCC medium chain triglyceride, CRODA 133 
International Plc, Snaith, UK) (Table 2). CRODAMOLTM GTCC was chosen as it is readily 134 
oxidised in the liver so has little impact on human health-related biomarkers(29, 30). Measurements 135 
were taken at day 0 and 21 of each treatment period.  The 6.2 g/d n-3 PUFA dose was comprised of 136 
four n-3 PUFA capsules in the morning and four n-3 PUFA capsules in the afternoon. To ensure an 137 
equal number of capsules were taken the 3.1 g/d n-3 PUFA comprised of two n-3 PUFA capsules 138 
and two placebo capsules in the morning and two n-3 PUFA capsules and two placebo capsules in 139 
the afternoon. All capsules (placebo and n-3 PUFA) were identical in appearance. 140 
Measurement of Pulmonary Function, EVH and Fraction of Exhaled Nitric Oxide (FENO) 141 
The EVH test was undertaken at day 0 and day 21 of each treatment and comprised 6 min of 142 
breathing dry gas at a target minute ventilation (V E) of 85% of the predicted maximal voluntary 143 
ventilation (MVV) (30 x baseline FEV1). Pulmonary function (forced vital capacity, FVC; FEV1; 144 
peak expiratory flow, PEF; and forced expiratory flow 25-75%, FEF25-75%) was assessed according 145 
to ATS/ERS guidelines(31) in triplicate at baseline and in duplicate at 3, 6, 16, 20, and 30 min after 146 
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EVH, as previously described. The highest values recorded were used for analyses. Baseline FENO 147 
was measured (NIOX MINO; Aerocrine, Solna, Sweden) according to ATS/ERS guidelines(32) in 148 
the HIB group only, as it is elevated in asthma patients but not in healthy controls(33). 149 
Urinary 9α, 11β-PGF2 Analysis 150 
Participants provided a urine sample at baseline and at 12, 60, and 90 min after EVH. 151 
Urinary concentration of 9α, 11β-PGF2, a metabolite of prostaglandin D2, was subsequently 152 
determined by enzyme-linked immunosorbent assay (Caymen Chemicals, Ann Arbor, Michigan, 153 
USA) and standardised for urinary creatinine concentration (ABX Pentra 400; Horiba, 154 
Northampton, UK) based on a kinetic method using alkaline picrate (Jaffe method)(34). The 155 
corrected 9α, 11β-PGF2 was expressed as ng/mmol creatinine. The inter- and intra-assay coefficient 156 
of variation was <15%. Two control participants and one HIB participant had samples at day 0 157 
below the limit of detection for urinary 9α, 11β-PGF2 (5 pg/ml) and were subsequently excluded 158 
from analysis.  159 
Neutrophil Phospholipid Fatty Acid Analysis 160 
The neutrophil phospholipid fatty acid composition was assessed as a measure of 161 
compliance to the treatments in addition to count of capsules returned after each treatment. 162 
Neutrophil cells were isolated from 20 mL of whole venous blood (drawn at baseline from an 163 
antecubital vein) through a 3 step purification protocol that consisted of dextran sedimentation 164 
(Fisher Scientific, Leicestershire UK), hypotonic lysis and Ficoll Paque sedimentation (GE 165 
Healthcare, Buckinghamshire, UK)(35). This method achieved up to 98% of pure neutrophils which 166 
were stored at -80°C under nitrogen until extraction of phospholipids using previously described 167 
methods(36). Fatty acid composition was analysed by gas chromatography as previously 168 
described(37). To identify the fatty acid methyl esters (FAME), retention times were compared 169 
against known standards, Supelco 37 component FAME mix and PUFA-3 menhaden oil (Sigma, 170 
Dorset, UK). EPA, DHA, arachidonic acid and linoleic acid were expressed as a percentage of total 171 
fatty acids.  172 
Statistical Analysis 173 
The average minimum perceptible improvement in FEV1 in adults with asthma is 230 174 
mL(38), whereas the within participant standard deviation for the fall in FEV1 after EVH is 100 175 
mL(21). A priori sample size calculation revealed that with power = 0.90 and alpha = 0.05, a sample 176 
size of 7 in the HIB group would be required to detect a 230 mL improvement in the fall in FEV1 177 
after EVH. 178 
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Data were analysed using SPSS (Chicago, IL). Following assessment for normality 179 
(Shapiro-Wilks test, skewness and kurtosis), data were analysed using repeated measures ANOVA 180 
and Bonferroni adjusted paired t-tests. Statistical significance was set at P < 0.05. Data presented 181 
are mean (SD) unless otherwise stated. Within treatment percent differences (from day 0 to day 21) 182 
for the fall in FEV1 following EVH were calculated as: ((% fall day 0 - % fall day 21)/ % fall day 0) 183 
× 100. For the HIB group, the individual percent protection afforded by the n-3 PUFA treatments 184 
compared with placebo was calculated for the % fall in FEV1 following EVH as: ((% fall day 21 185 
placebo - % fall day 21 treatment) / % fall day 21 placebo) × 100. In the HIB group, the overall 186 
severity of HIB was determined by calculating the area under the curve for % fall in FEV1 after 187 
EVH (AUC0–30) using the trapezoidal rule.  188 
Results 189 
Pulmonary Function and Ventilation Rate during EVH 190 
Baseline FEV1 was lower in the HIB group (3.75 (SD 0.81) L) than the control group (4.63 191 
(SD 0.37) L) (P = 0.017), and FVC tended to be lower in the HIB group (4.66 (SD 0.06) L) than the 192 
control group (5.26 (SD 0.39) L) (P = 0.051). There were no within group differences in FEV1 or 193 
FVC measured at day 0 between the three treatments. 194 
As expected, at day 0 there was a greater peak fall in FEV1 after EVH in the HIB group 195 
(pooled data: -29 (SD 17) %) than the control group (pooled data: -3 (SD 2) %) (P = 0.001). In the 196 
control group, there was no effect of treatment or day on the peak fall in FEV1 after EVH. In the 197 
HIB group, there was a treatment × day interaction for the peak fall in FEV1 after EVH (P = 0.011). 198 
Further analyses revealed an effect of treatment for the peak fall in FEV1 after EVH at day 21 (P = 199 
0.001). Specifically, the peak fall in FEV1 after EVH was reduced by 34 (SD 14) % (-690 (SD 460) 200 
mL) after 6.2 g/d n-3 PUFA (mean difference = 310 (SD 150) mL, 95% CI = 185, 432 mL, P = 201 
0.001, effect size = 0.70), and by 30 (SD 11) % (-700 (SD 420) mL) after 3.1 g/d n-3 PUFA (mean 202 
difference = 270 (SD 120) mL, 95% CI = 170, 377 mL, P = 0.001, effect size = 0.58). The reduced 203 
peak falls in FEV1 after 6.2 g/d and 3.1 g/d n-3 PUFA were not different (P = 0.834) (Figure 2, 204 
Table 4). The percent protection afforded by the n-3 PUFA treatments compared with placebo is 205 
shown in Table 4. The peak fall in FEV1 was unchanged from day 0 to day 21 of placebo.  206 
Figure 3 shows the percent change in FEV1 during 30 min recovery after EVH in the HIB 207 
group. At day 0, the percent change in FEV1 during recovery was not different between treatments. 208 
At day 21, the percent change in FEV1 was reduced for up to 20 and 30 min recovery after 6.2 g/d 209 
and 3.1 g/d n-3 PUFA, respectively. Furthermore, compared with placebo at day 21, the percent 210 
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change in FEV1 was lower for up to 6 and 20 min recovery after 6.2 g/d and 3.1 g/d n-3 PUFA, 211 
respectively. 212 
In the HIB group, there was a treatment x day interaction for AUC0–30 (P = 0.004). Further 213 
analysis revealed that at day 21 the AUC0–30 was reduced after 6.2 g/d (-415 (SD 382), P = 0.002) 214 
and 3.1 g/d (-398 (SD 399), P = 0.001) n-3 PUFA compared with placebo (-595 (SD 424)). The 215 
AUC0–30 at day 21 of 6.2 g/d and 3.1 g/d n-3 PUFA was not different (P = 0.751). 216 
Consistent with our previous findings(21, 39) the peak fall in FEV1 after EVH in the HIB 217 
group was reproducible with no differences occurring between day 0 of the three treatments (within 218 
participant CV = 7 (SD 4) %; measurement error = 84 mL; reproducibility = 231 mL; smallest 219 
meaningful change = 115 mL). The peak fall in FVC showed similar outcomes. At day 0 of the 220 
three treatments the peak fall in FVC was greater in the HIB group (pooled data: -992 (SD 604) mL; 221 
-21 (SD 15) %) than the control group (pooled data: -140 (SD 90) mL; -3 (SD 2) %) (P = 0.004). In 222 
the control group, the peak fall in FVC was unchanged after placebo and both doses of n-3 PUFA. 223 
The peak fall in FVC after EVH at day 0 was reduced by 30 (SD 21) % after 6.2 g/d n-3 PUFA and 224 
by 29 (SD 24) % after 3.1 g/d n-3 PUFA but was unchanged after placebo in the HIB group. The 225 
reduced peak fall in FVC after 6.2 g/d and 3.1 g/d n-3 PUFA was not different (P = 0.847). In the 226 
HIB group, the peak fall in PEF was unchanged after placebo and both n-3 PUFA treatments 227 
(pooled data: -2.52 (SD 1.68) L/s). In the HIB group, the peak fall in FEF25-75% was reduced from 228 
day 0 (-1.55 (SD 0.37) L/s) to day 21 (-1.24 (SD 0.45) L/s) of 6.2 g/d n-3 PUFA (mean difference = 229 
0.31 (SD 0.23) L/s, 95% CI = 0.12, 0.50 L/s, P = 0.006, effect size = 0.77). In the HIB group, the 230 
peak fall in FEF25-75% was unchanged after 3.1g/d n-3 PUFA and placebo in the HIB group, and 231 
after all treatments in the control group (P > 0.05).  232 
Minute ventilation achieved during each of the six EVH trials did not differ in the HIB 233 
group (P > 0.05; between trial CV = 0.23) (pooled data: 109.5 ± 21.4 L/min; 78 ± 18% of MVV 234 
target) which was less compared with the control group (P = 0.001; between trial CV = 0.09) 235 
(pooled data: 133.4 ± 10.8 L/min; 60 ± 6% of MVV target).  236 
Fraction of Exhaled Nitric Oxide 237 
 In the HIB group, there was a treatment × day interaction for FENO (P = 0.004). After 6.2 238 
g/d n-3 PUFA, FENO was reduced by 24% from day 0 (48 (SD 33) ppb) to day 21 (35 (SD 28) ppb) 239 
(mean difference = 13 (SD 12) ppb, 95% CI = 3, 24 ppb, P = 0.020, effect size = 0.41). Similarly, 240 
after 3.1 g/d n-3 PUFA, FENO was reduced by 31% from day 0 (49 (SD 33) ppb) to day 21 (34 (SD 241 
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28) ppb) (mean difference = 15 (SD 14) ppb, 95% CI = 4, 27 ppb, P = 0.018, effect size = 0.46) 242 
(Figure 4). The reduced FENO after 6.2 g/d and 3.1 g/d n-3 PUFA was not different (P = 0.491) 243 
(Figure 4). FENO remained unchanged from day 0 (47 (SD 26) ppb) to day 21 (47 (SD 27) ppb) of 244 
placebo. 245 
Urinary 9α, 11ß PGF2 246 
Baseline urinary 9α, 11ß PGF2 did not differ between the HIB group (day 0 pooled data: 247 
40.85 (SD 21.49) ng/mmol creatinine) and the control group (day 0 pooled data: 27.05 (SD 14.01) 248 
ng/mmol creatinine) (P = 0.133).  There were no within-group differences in urinary 9α, 11ß PGF2 249 
measured before EVH at day 0 and day 21 of the three treatments.  250 
At day 0, urinary 9α, 11ß PGF2 increased by 31.53 (SD 22.77) ng/mmol creatinine (pooled 251 
data) after EVH in the HIB group (P = 0.030) but not in the control group (pooled data: 11.11 (SD 252 
16.30) ng/mmol creatinine). At day 0, changes in 9α, 11ß PGF2 after EVH were different between 253 
groups (P = 0.003). In the HIB group, subsequent analyses revealed an effect of treatment on the 254 
peak increase in 9α, 11ß PGF2 after EVH at day 21 (P = 0.014). Specifically, the peak increase in 255 
9α, 11ß PGF2 after EVH was reduced after 6.2 g/d n-3 PUFA (mean difference = 11.75 (SD 7.42) 256 
ng/mmol creatinine, 95% CI = 5.54, 17.96 ng/mmol creatinine, P = 0.009, effect size = 0.50) and 257 
3.1 g/d n-3 PUFA (mean difference = 12.86 (SD 14.90) ng/mmol creatinine, 95% CI = 0.40, 25.33 258 
ng/mmol creatinine, P = 0.041, effect size = 0.40). The reduced peak increase in 9α, 11ß PGF2 after 259 
EVH following 6.2 g/d and 3.1 g/d n-3 PUFA was not different (P = 0.377) (Figure 5). There was 260 
no effect of placebo on the increase in urinary 9α, 11ß PGF2 after EVH.  261 
Compliance Assessment - Neutrophil Phospholipid Fatty Acid Content, and Capsule Counts 262 
Good compliance to all treatments was shown from the capsule counts in both the HIB and 263 
control groups (Table 3). Further compliance evidence was provided from the neutrophil 264 
phospholipid fatty acid content. In the HIB group, 6.2 g/d n-3 PUFA increased EPA (P = 0.002) and 265 
DHA (P = 0.045) content, and reduced arachidonic acid (P = 0.005). In the HIB group, 3.1 g/d n-3 266 
PUFA increased EPA content (P = 0.018) and reduced arachidonic acid (P = 0.009); there was a 267 
trend for an increase in DHA content (P = 0.074). In the HIB group, linoleic acid content was 268 
unchanged after 6.2 g/d and 3.1 g/d n-3 PUFA. Phospholipid fatty acid content was unchanged after 269 
placebo in both groups. In the control group, 6.2 g/d n-3 PUFA tended to increase EPA (P = 0.054) 270 
and DHA content (P = 0.087), whereas 3.1 g/d n-3 PUFA increased DHA content (P = 0.007) and 271 
reduced arachidonic acid (P = 0.038); EPA content was unchanged (Table 3).  272 
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 273 
Discussion 274 
Previous research has shown that high doses of n-3 PUFA (5.2-5.4 g/d) reduce the severity 275 
of HIB and EIB(10, 11, 15-17). The present study demonstrates that a lower dose of 3.1 g/d n-3 PUFA is 276 
equally effective in reducing HIB in adult men with asthma. The 6.2 and 3.1 g/d n-3 PUFA 277 
treatments also resulted in similar reductions in baseline FENO, and comparable suppression of 278 
urinary 9α, 11β-PGF2 after EVH. These findings suggest that 3.1 g/d n-3 PUFA could be used as an 279 
adjunct therapy for physically active adults with asthma and EIB. The percent protection afforded 280 
by 6.2 g/d n-3 PUFA (35 (SD 14) %) and 3.1 g/d n-3 PUFA (33 (SD 12) %) highlights the efficacy 281 
of n-3 PUFA as an adjunct therapy. The  percent protection afforded by n-3 PUFA is comparable to 282 
montelukast (50mg twice daily)(40) but less than the 60-70% protection afforded by short-acting β2-283 
agonists procaterol (10 micrograms/inhalation) and albuterol (90 micrograms/inhalation)(41). Long-284 
acting β2-agonists also provide effective treatment for EIB,
(42-44) although chronic treatment with 285 
both long- and short-acting β2-agonists can result in tolerance
(45, 46). Furthermore, compliance to the 286 
lower 3.1 g/d n-3 PUFA dose may be improved due to reduced capsule numbers, reduce cost and 287 
risk of gastrointestinal distress, which is commonly associated with bloating, and stomach upset. 288 
Indeed, two participants withdrew from the study when on the 6.2 g/d n-3 PUFA treatment due to 289 
gastrointestinal distress, whereas full compliance and no participant withdrawals (capsule counts) 290 
was observed with 3.1 g/d n-3 PUFA.  291 
The EVH test is an indirect bronchial provocation test that is a suitable objective surrogate 292 
for identifying EIB(24). We have previously reported that the EVH protocol used in the present study 293 
elicits a highly reproducible fall in FEV1
(21, 39) which is crucial when assessing treatment efficacy. 294 
The ~290 mL (~32%) decrease in the post-EVH fall in FEV1 after 6.2 g/d and 3.1 g/d n-3 PUFA 295 
supplementation exceeds the minimum perceptible change of 230 mL(38) and is therefore clinically 296 
relevant. Our findings are in agreement with previous studies showing an attenuation of HIB(17) and 297 
EIB(11) after n-3 PUFA supplementation in adults with asthma. These findings collectively support 298 
the ATS/ERS guidance(25) suggesting n-3 PUFA supplementation could be of benefit in individuals 299 
with EIB. Our findings are also in broad agreement with work on n-3 PUFA supplementation in 300 
elite athletes with EIB(10), and asthmatic patients with EIB and HIB(11, 15-17). An interesting 301 
difference is that previous work showed abolition of EIB after n-3 PUFA supplementation(10), 302 
whereas in the present study only 3 participants became non-diagnostic (Figure 2). This may be 303 
partly due to inter-study differences in the severity of EIB: the peak fall in FEV1 in the present 304 
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study (-30%) was ∼50% greater than that reported in previous n-3 PUFA supplementation studies 305 
demonstrating a reduction in EIB/HIB(11, 15-17). 306 
Unlike the rather consistent finding that pharmacological therapy reduces EIB(42-44), the 307 
efficacy of n-3 PUFA remains controversial. Our findings contrast those of Arm et al.(9)  and 308 
Brannan et al.(12) who despite using relatively high n-3 PUFA doses (5.4-6.0 g/d), reported no 309 
change in bronchial hyperresponsiveness to inhaled histamine and mannitol, respectively. Arm et 310 
al.(9) reported no change in airway resistance (fall in FEV1 was not measured) after a cycling 311 
exercise challenge, although their data are confounded by: (1) the suggestion that low-grade, non-312 
pharmaceutical n-3 PUFA was used(47); (2) low statistical power due to the small number of 313 
participants (n = 6) performing the exercise; (3) exercise being performed at ambient temperature 314 
and humidity, which may result in insufficient environmental stress; and (4) the low exercise 315 
intensity (60-130 W) which likely (data not measured/reported) elicited only a modest increase in 316 
V E. The efficacy of n-3 PUFA supplementation may also partly depend on the choice of bronchial 317 
provocation test. Direct bronchial provocation tests such as inhaled histamine act directly on 318 
receptors on the airway smooth muscle causing contraction(48) and may not, therefore, fully reveal 319 
the potential anti-inflammatory effects of n-3 PUFA. Indirect bronchial provocation tests such as 320 
mannitol and EVH both alter the tonicity and volume of the airway surface liquid thereby 321 
promoting the release of bronchoconstrictive inflammatory mediators(49, 50). However, mannitol and 322 
EVH may exert different levels of osmotic and mechanical stress on the airways. Specifically, 323 
mannitol induces dehydration stress primarily in the proximal airways(50, 51), whereas the high V E 324 
during EVH results in the dehydration stress being extended to peripheral airways(52) which are 325 
increasingly recruited to heat and humidify inspired air. Furthermore, EVH also elicits airflow-326 
induced shear stress and high transepithelial pressure gradients(53). These differences may 327 
predispose the airway epithelium to greater damage after EVH than mannitol; indeed, EVH tends to 328 
result in greater increases in urinary Clara cell protein 16 concentration, a marker of airway 329 
epithelial damage(54, 55). This is significant because n-3 PUFA supplementation attenuates the 330 
increase in urinary Clara cell protein concentration after EVH, which suggests that reduced HIB 331 
may be partly due to reduced airway epithelial damage(56). Differences in the intensity of the 332 
stimulus to the airways may thus explain the divergent effects of n-3 PUFA supplementation on 333 
bronchial hyperresponsiveness to EVH and mannitol.  334 
Recently, Price et al.(18) reported no change in the severity of HIB or markers of airway 335 
inflammation (FENO, urinary 9α, 11ß PGF2 and cysteinyl leukotriene E4) in recreationally active 336 
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adults supplemented daily with a combined treatment of 30 µg vitamin D3 with n-3 PUFA (3.0 g 337 
EPA and 2.0 g DHA). Unfortunately, objective treatment compliance measures (e.g. neutrophil 338 
phospholipid DHA and EPA content) were not taken in this study. The fall in FEV1 after EVH was 339 
also modest (∼16%) compared with the ~30% fall observed at day 0 in the present study, and 6 340 
from 10 of the participants did not have physician diagnosed asthma (and consequently no asthma 341 
medication). Two participants in Price et al.(18) also became non-diagnostic for HIB after the 342 
placebo treatment. It may be that n-3 PUFA supplementation is thus more effective in individuals 343 
with diagnosed asthma and more severe HIB, as observed in the present study.   344 
The increase in urinary 9α, 11β-PGF2 after EVH at day 0 in the HIB group is similar in 345 
magnitude to that reported previously in adults with asthma performing exercise or EVH(10, 57). The 346 
reduced increase in 9α, 11β-PGF2 after EVH was comparable after 6.2 g/d and 3.1 g/d n-3 PUFA 347 
supplementation. Previous work also reports a reduced increase in 9α, 11β-PGF2 after EVH 348 
following n-3 PUFA supplementation(10). The increased EPA and DHA cell membrane content 349 
following n-3 PUFA supplementation is likely to result in dual inhibition of arachidonic acid-350 
dependent cyclooxygenase and 5-lipoxygenase pathways which are responsible for eicosanoid 351 
generation(7). This may explain the decrease in 9α, 11β-PGF2, a metabolite of the arachidonic acid-352 
derived pro-inflammatory eicosanoid prostaglandin-D2. The osmotic changes in the airways 353 
following EVH results in mast cell activation and release of PGD2 during bronchoconstriction(49, 50). 354 
Suppression of mast cell activation, and reduced eicosanoid generation, may thus partially explain 355 
reduced HIB after n-3 PUFA supplementation.  356 
The comparable reduction in baseline FENO after 6.2 g/d and 3.1 g/d n-3 PUFA 357 
supplementation concurs with previous work(17, 58) and is indicative of reduced baseline eosinophilic 358 
airway inflammation. Increased FENO can also result from elevated expression of inducible nitric 359 
oxide synthase in T-cells, macrophages, airway epithelial cells, and other inflammatory cells within 360 
the airways(59, 60). Elevated expression of inducible nitric oxide synthase can be induced by certain 361 
pro-inflammatory cytokines such as TNF-α(59, 60) probably via the activation of nuclear factor-kappa 362 
β transcription factor(61). The n-3 and n-6 PUFAs modulate nuclear factor-kappa β transcription 363 
factor activation(62) and presumably therefore TNF-α expression, which may explain the observed 364 
fall in FENO after n-3 PUFA supplementation in the present study. Support for this argument comes 365 
from work showing that 5.4 g/d n-3 PUFA suppresses circulating plasma TNF-α in athletes with 366 
EIB(10). The comparable reduction in both baseline FENO and the post-EVH increase in 9α, 11β-367 
PGF2 after 6.2 g/d and 3.1 g/d n-3 PUFA supplementation suggests that both doses increased the n-368 
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3 PUFA content of the phospholipid bilayer of cell membranes to influence the inflammatory 369 
response. Furthermore, and consistent with previous reports(17, 56), the lower FENO observed after n-370 
3 PUFA supplementation in the present study may have resulted from an increase in airway pH, 371 
which is considered a determinant of FENO and airway inflammation
(63).  372 
Limitations of the current study include no run-in period to assess habitual n-3 PUFA intake, 373 
the exclusion of females, the comparatively low participant numbers, and the wide range of asthma 374 
phenotypes suggested by the heterogeneous fall in FEV1 and large variation in inflammatory 375 
markers after EVH. However, our cohort provides evidence for the use of n-3 PUFA in more severe 376 
HIB than previous literature(10, 11). Future work may explore whether particular asthma phenotypes 377 
and HIB/EIB severity respond preferentially to n-3 PUFA supplementation. Furthermore, given the 378 
existing inter-study differences regarding the efficacy of n-3 PUFA for the management of EIB, 379 
further studies using larger sample sizes are warranted.  380 
In conclusion, 3.1 g/d n-3 PUFA supplementation effectively reduced HIB in men with 381 
asthma to a similar extent as a higher dose. Lower doses of n-3 PUFA thus represent a potentially 382 
beneficial adjunct treatment for adults with asthma and EIB, whilst also reducing the burden of cost, 383 
compliance and potential gastrointestinal distress. Further studies are needed to elucidate if the 384 
bronchial provocation test used and the severity of asthma and HIB/EIB affect the degree of 385 
protection afforded by n-3 PUFA supplementation.  386 
 387 
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 404 
TABLE 1. Individual and mean (SD) anthropometric data, baseline pulmonary function, and 405 
medication. 406 
    FVC (L) FEV1 (L)  
 Age (y) Height (cm) Body Mass (kg) n % n % Medications 
HIB         
1 21 177 75 5.54 106 4.54 103 S 
2 44 178 87 4.22 94 3.17 87 S, BUD+FORM 
3 21 173 58 3.78 76 2.77 65 S, BUD+FORM 
4 38 180 77 4.62 95 3.80 95 S 
5 38 173 83 4.43 91 3.49 90 S 
6 28 177 68 4.91 96 4.31 100 S 
7 22 181 82 5.70 107 5.10 114 S 
8 31 173 75 4.10 91 2.84 76 S, BEC 
Mean (SD) 30 (9) 177 (3) 76 (9) 4.66 (0.68) 95 (10) 3.75 (0.84)* 91 (16)  
Control               
1 30 183 80 5.30 98 4.15 92  
2 20 184 80 5.93 106 5.18 110  
3 20 178 69 4.61 88 4.49 101  
4 28 170 84 4.87 103 4.18 104  
5 26 184 70 5.23 93 4.90 104  
6 23 189 92 5.34 91 5.00 102  
7 27 177 69 5.31 103 4.45 103  
8 27 181 88 5.46 101 4.69 104   
Mean (SD) 25 (4) 181 (6) 79 (9) 5.26 (0.39) 98 (7) 4.63 (0.38) 103 (7)   
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BEC = beclomethasone; BUD = budesonide; FORM = formoterol; FEV1 = forced expiratory volume in 1 second; FVC 407 
= forced vital capacity; S = salbutamol. *Difference between HIB and control group (P = 0.017). 408 
 409 
 410 
 411 
TABLE 2. Fatty acid composition (% total fatty acids) of the n-3 PUFA (INCROMEGATM 412 
TG4030) and placebo (CRODAMOLTM GTCC, medium chain triglycerides) treatments. Individual 413 
fatty acids making up ≥ 1% are shown. 414 
 % total fatty acids  
Fatty Acid Name 
n-3 PUFA (INCROMEGA™ 
TG4030) 
Placebo (CRODAMOLTM 
GTCC) 
8:0 Caprylic acid  56 
10:0 Capric acid  43 
18:4 n-3 Octadecatetraenoic acid 3  
20:4 n-6 Arachidonic acid 3  
20:4 n-3 Eicosatetraenoic acid 2  
20:5 n-3 Eicosapentaenoic acid 45  
21:5 n-3 Heneicosapentaenoic acid 2  
22:5 n-3 Docosapentaenoic acid 6  
22:6 n-3 Docosahexaenoic acid 31  
Total  92 99 
 415 
 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
 424 
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 425 
 426 
 427 
TABLE 3. Treatment adherence (%) based on capsule count, and fatty acid composition of 428 
neutrophil extracts expressed as a percent weight of total fatty acids at day 0 and day 21 of each 429 
treatment in HIB and control groups. Data are mean (SD).  430 
 
HIB 
Placebo 6.2 g/d n-3 PUFA 3.1 g/d n-3 PUFA 
Day 0 Day 21 Day 0 Day 21 Day 0 Day 21 
20:4 n-6 Arachidonic Acid 6.52 (0.82) 6.34 (0.62) 6.03 (0.78) 5.37 (0.80)** 6.35 (0.92) 5.26 (0.99)** 
20:5 n-3 EPA 0.72 (0.17) 0.75 (0.19) 0.77 (0.19) 1.39 (0.38)** 0.59 (0.29) 1.05 (0.31)* 
22:6 n-3 DHA 2.15 (0.33) 2.20 (0.37) 2.06 (0.33) 2.39 (0.31)* 2.14 (0.40) 2.29 (0.35) 
Adherence (%)  93 (4)  94 (4)  95 (4) 
Control       
20:4 n-6 Arachidonic Acid 5.18 (1.02) 5.09 (1.34) 5.20 (0.63) 4.94 (0.56) 5.73 (1.29) 5.02 (1.01)* 
20:5 n-3 EPA 0.80 (0.19) 0.79 (0.22) 0.70 (0.20) 0.93 (0.12) 0.73 (0.21) 0.84 (0.10) 
22:6 n-3 DHA 1.98 (0.31) 2.14 (0.45) 2.02 (0.28) 2.30 (0.30) 1.83 (1.40) 2.22 (0.26)** 
Adherence (%)  93 (6)  92 (5)  93 (4) 
DHA = Docosahexaenoic acid; EPA = Eicosapentaenoic acid; HIB = Hyperpnoea-induced bronchoconstriction.  431 
Difference between day 0 and day 21 within treatment (* P < 0.05; ** P < 0.01). 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
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 442 
 443 
 444 
TABLE 4. Individual and mean (SD) peak % fall in FEV1 at day 0 and day 21 of each treatment 445 
and percent protection afforded by n-3 PUFA. Data shown for HIB group only.  446 
 Peak % fall in FEV1 Percent protection afforded by n-3 PUFA 
treatments for peak % fall in FEV1  Placebo 6.2 g/day n-3 PUFA 3.1 g/day n-3 PUFA 
HIB Day 0 Day 21 Day 0 Day 21 Day 0 Day 21 6.2 g/day n-3 PUFA 3.1 g/day n-3 PUFA 
1 -12.58 -13.10 -13.02 -6.54 -14.95 -9.98 50 24 
2 -63.22 -64.81 -61.04 -51.36 -60.32 -49.84 21 23 
3 -48.73 -47.40 -48.20 -33.70 -48.92 -32.83 29 31 
4 -32.90 -28.10 -28.50 -19.54 -30.45 -22.91 30 18 
5 -27.02 -32.64 -29.71 -14.98 -26.44 -23.12 54 29 
6 -19.72 -18.01 -17.33 -11.67 -18.41 -10.50 35 42 
7 -17.74 -16.21 -16.05 -8.64 -13.04 -8.63 47 47 
8 -14.83 -15.82 -15.71 -13.67 -13.78 -7.90 14 50 
Mean (SD) -30 (18) -30 (18) -29 (17) -20 (15) -28 (18) -21 (15) 35 (14) 33 (12) 
Percent protection afforded by the n-3 PUFA treatments calculated as: ((% fall day 21 placebo - % 447 
fall day 21 treatment) / % fall day 21 placebo) × 100. 448 
 449 
Figure Captions 450 
FIGURE 1 – Participant flow diagram. HIB = hyperpnoea-induced bronchoconstriction; CTRL = controls; PUFA = 451 
polyunsaturated fatty acid; GI = gastrointestinal. 452 
FIGURE 2 – Peak falls in forced expiratory volume in 1 s (FEV1) before and after placebo (A), 6.2 g/d n-3 PUFA (B), 453 
and 3.1 g/d n-3 PUFA (C) in the HIB group (n = 8). Bars represent mean (SD) and identical symbols represent the same 454 
HIB participant. *Day 0 v. day 21 (P = 0.001). 455 
FIGURE 3 – The percent change in forced expiratory volume in 1 second (FEV1) after eucapnic voluntary hyperpnoea 456 
in participants with hyperpnoea-induced bronchoconstriction (HIB). A 10% fall in FEV1 (shown by the dashed line) is 457 
diagnostic of HIB. Closed circles, day 0 of placebo treatment; open circles, day 21 of placebo treatment; closed 458 
squares, day 0 of 6.2 g/d n-3 PUFA treatment; open squares, day 21 of 6.2 g/d n-3 PUFA; closed triangles, day 0 of 3.1 459 
g/d n-3 PUFA; open triangles, day 21 of 3.1 g/d n-3 PUFA. Significant differences indicated by letters: a, 6.2 g/d n-3 460 
PUFA vs. placebo; b, 3.1 g/d n-3 PUFA vs. placebo; c, day 0 vs. day 21 of 6.2 g/d n-3 PUFA; d, day 0 vs. day 21 of 3.1 461 
g/d n-3 PUFA. Single letters, P < 0.05; *P < 0.01; **P < 0.001.  462 
FIGURE 4 – Baseline fraction of exhaled nitric oxide (FENO) before and after placebo (A), 6.2 g/d n-3 PUFA (B), and 463 
3.1 g/d n-3 PUFA (C) in the HIB group (n = 8). Bars represent mean (SD) and identical symbols represent the same 464 
HIB participant. *Day 0 v. day 21 (P < 0.05). 465 
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FIGURE 5 - Peak increase in urinary 9α, 11ß PGF2 after EVH in the HIB group (n = 8). Filled and open bars represent 466 
day 0 and day 21, respectively, of the treatment. Data are mean (SD). *Day 0 v. day 21 (P < 0.05  467 
 468 
 469 
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FIGURE 1 – Participant flow diagram. HIB = hyperpnoea-induced bronchoconstriction; CTRL = controls; 
PUFA = polyunsaturated fatty acid; GI = gastrointestinal.  
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FIGURE 2 – Peak falls in forced expiratory volume in 1 s (FEV1) before and after placebo (A), 6.2 g/d n-3 
PUFA (B), and 3.1 g/d n-3 PUFA (C) in the HIB group (n = 8). Bars represent mean (SD) and identical 
symbols represent the same HIB participant. *Day 0 v. day 21 (P = 0.001).  
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FIGURE 3 – The percent change in forced expiratory volume in 1 second (FEV1) after eucapnic voluntary 
hyperpnoea in participants with hyperpnoea-induced bronchoconstriction (HIB). A 10% fall in FEV1 (shown 
by the dashed line) is diagnostic of HIB. Closed circles, day 0 of placebo treatment; open circles, day 21 of 
placebo treatment; closed squares, day 0 of 6.2 g/d n-3 PUFA treatment; open squares, day 21 of 6.2 g/d 
n-3 PUFA; closed triangles, day 0 of 3.1 g/d n-3 PUFA; open triangles, day 21 of 3.1 g/d n-3 PUFA. 
Significant differences indicated by letters: a, 6.2 g/d n-3 PUFA vs. placebo; b, 3.1 g/d n-3 PUFA vs. 
placebo; c, day 0 vs. day 21 of 6.2 g/d n-3 PUFA; d, day 0 vs. day 21 of 3.1 g/d n-3 PUFA. Single letters, P 
< 0.05; *P < 0.01; **P < 0.001.  
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FIGURE 4 – Baseline fraction of exhaled nitric oxide (FENO) before and after placebo (A), 6.2 g/d n-3 PUFA 
(B), and 3.1 g/d n-3 PUFA (C) in the HIB group (n = 8). Bars represent mean (SD) and identical symbols 
represent the same HIB participant. *Day 0 v. day 21 (P < 0.05).  
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FIGURE 5 - Peak increase in urinary 9α, 11ß PGF2 after EVH in the HIB group (n = 8). Filled and open bars 
represent day 0 and day 21, respectively, of the treatment. Data are mean (SD). *Day 0 v. day 21 (P < 
0.05  
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